Updat3
Search
Sign in

Gen Z Questions Long-Term SSRI Use Amid Growing Concerns

Topic: healthRegion: north americaUpdated: i1 outletsSources: 1Spectrum: Right OnlyFiltered: US/Canada (1/1)· Clear⏱ 3 min read
📰 Scored from 1 outletsacross 1 RightHow we score bias →
Story Summary
SITUATION
Gen Z individuals are increasingly questioning the long-term use of SSRIs, citing concerns over insufficient research on side effects. Ella Emhoff, a prominent Gen Z figure, has publicly shared her struggles with discontinuing SSRIs, highlighting a broader generational issue.
Coveragetap to expand ▾
Spectrum: Right Only🌍US: 1
Political Spectrum
Position is inferred from coverage mix.
i1 outlets · Right
Left
Center
Right
Left: 0
Center: 0
Right: 1
Geography Coverage
Distribution of where coverage is coming from.
i1 unique outlets · Dominant: US/Canada
KEY FACTS
  • Gen Z individuals are increasingly questioning the long-term use of SSRIs due to concerns about side effects (per nypost.com).
  • Emhoff began taking SSRIs at around 11 years old, highlighting early prescription practices (per nypost.com).
  • Concerns are rising about the lack of research on the long-term effects of SSRIs (per nypost.com).
  • Robert F. Kennedy Jr. has been cited as a figure whose views resonate with some questioning the widespread use of SSRIs (per nypost.com).
HISTORICAL CONTEXT

This development falls within the broader context of Health activity in North America.

Current reporting indicates: GenZ’ers who have spent half their lives on SSRIs are finally starting to question the risks — and find themselves agree Gen Z is finally waking up and realizing that they were mass-prescribed antidepressants without much consideration for the long-term side effects.

Brief

Gen Z, the generation born between the late 1990s and early 2010s, is increasingly questioning the long-term use of selective serotonin reuptake inhibitors (SSRIs), a class of drugs commonly prescribed for depression and anxiety. This shift in perspective is driven by concerns over the lack of comprehensive research on the long-term side effects of these medications.

Among those voicing their concerns is Ella Emhoff, the 26-year-old stepdaughter of Kamala Harris, who recently took to TikTok to share her struggles with discontinuing SSRIs after more than a decade of use. Emhoff's experience underscores a broader issue faced by many in her generation who were prescribed these medications at a young age.

Emhoff revealed to her 60,000-plus TikTok followers that she began taking SSRIs when she was around 11 years old. Her candid disclosure has sparked a conversation about the early prescription practices and the potential long-term impacts of such medications.

This conversation is gaining momentum on social media platforms, where young people are increasingly sharing their personal experiences and concerns. A 2025 survey published in the BMJ Mental Health journal found that 16.5% of Americans aged 18 to 24 are currently taking antidepressants, amounting to over 5 million young individuals.

This statistic highlights the widespread reliance on SSRIs among young people and raises questions about the adequacy of research into their long-term effects. The concerns raised by Gen Z are not without precedent.

Critics of the pharmaceutical industry have long argued that the long-term impacts of SSRIs have not been sufficiently studied, leaving many users uncertain about the potential risks associated with prolonged use. Robert F.

Kennedy Jr., a prominent figure known for his skepticism of certain pharmaceutical practices, has been cited as a voice that resonates with some of these concerns. The growing discourse around SSRIs among Gen Z reflects a broader questioning of medical practices that prioritize medication over other forms of treatment.

As more individuals share their experiences and concerns, there is a call for more comprehensive research and a reevaluation of prescription practices. This shift in perspective among Gen Z could have significant implications for the pharmaceutical industry and healthcare providers.

It underscores the need for greater transparency and research into the long-term effects of medications that are widely prescribed to young people. As the conversation continues to unfold,

Why it matters
  • Gen Z individuals, particularly those prescribed SSRIs at a young age, face potential long-term health risks due to insufficient research on side effects.
  • The pharmaceutical industry may face increased scrutiny and demand for transparency regarding the long-term effects of SSRIs.
  • Healthcare providers could be pressured to reevaluate prescription practices and consider alternative treatments for depression and anxiety.
What to watch next
  • Whether healthcare providers will adjust prescription practices for SSRIs in response to growing concerns.
  • The potential for increased research funding into the long-term effects of SSRIs.
  • How the pharmaceutical industry will address the scrutiny over SSRI prescription practices.
Where sources differ
7 dimensions
Framing differences
?
  • nypost.com highlights Ella Emhoff's personal experience as a focal point for the broader generational issue.
Disputed or unclear
?
  • No source disputes the increase in Gen Z questioning SSRI use, but the extent of the impact remains unclear.
Omitted context
?
  • No source mentions the role of pharmaceutical companies in promoting SSRIs or the potential influence of industry-funded research.
Conflicting figures
?
  • nypost.com cites a 2025 survey indicating 16.5% of young Americans take antidepressants.
Disputed causality
?
  • Sources agree on the growing concern among Gen Z but do not specify a single cause for the shift.
Attribution disputes
?
  • nypost.com attributes the questioning of SSRIs to both personal experiences and public figures like Robert F. Kennedy Jr.
Sources
1 of 1 linked articles · Filter: US/Canada